Amendments to the Specification

Please amend the specification at ¶ [0012] as follows:

--The present invention is based, in part, on the discovery that the modified version of Peptide G (CEL-1000) (Asn Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile - SEQ ID NO. 5) obtained by replacing Asn with Asp to form derG (~~Asp~~ Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile - SEQ ID NO. 18), ~~optionally having~~ where Xaa at position 1 can be Asp or Ala, and when Xaa is Ala, then cyclohexylalanine, D-alanine, and also having acetyl, ClAc, or BrAc at position 1, has significantly more potent biological activity than the parent molecule, another form being (~~Asp~~ Xaa Gly Gln Glu Glu Xaa Ala Gly Val Val Ser Thr Gly Leu Ile Gly Gly Gly - SEQ ID NO. 7) ~~optionally having~~ where Xaa at position 1 can be Asp or Ala, and when Xaa is Ala, then cyclohexylalanine, D-alanine, and also having acetyl, ClAc, or BrAc at position 1 and amidation at position 18 where Xaa is an amino acid Val, Leu, Ile, Gly or Ala. The peptides enhance the immune response, particularly the CD4 related (cell mediated) response, independent of being supplied as a conjugated peptides (L.E.A.P.S.™ constructs) as previously described. Isoaspartic acid is not used since it is not naturally found in proteins or encoded by the genetic code. Accordingly, the present invention enables the development of compositions useful as a pharmaceutical, adjuvant, immunostimulant or immunomodulator to activate the immune system wherein the compositions may be peptides, non-peptide mimetics or organic molecules selected from aliphatics, carbohydrates, heterocyclics, aromatics, substituted forms and mixtures thereof.--